Deniz Can Guven: The OS benefits of cancer drugs approved by surrogate endpoints

Deniz Can Guven, The Editorial Board Member in BMC Cancer, shared on X:

“Out in The Lancet Oncology in OA. The OS benefits of cancer drugs approved by surrogate endpoints.

• 38 indications with OS data after approval
• Significant OS benefit in only 32% of the indications
• Late availability of (>3 years) non-significant OS results

The value of surrogate endpoints in approvals. A double-edged sword.”

Source: Deniz Can Guven/X